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INTRODUCTION
The major lipids of human body are phospholipids, choles-
terol, triglycerides and cholesteryl esters. These insoluble
lipids are transported through blood as lipoprotein com-
plexes of lipids and one or more specific proteins, called
apolipoproteins. By actively exchanging certain lipids and
apolipoproteins with each other, the lipoproteins are synthe-
sized and degraded at a constant rate. Among lipoproteins,
low density lipoprotein (LDL) is 75% lipid (cholesterol and
cholesteryl esters) and 25% protein. LDL is the metabolic
product of very low density lipoprotein (VLDL). The high
level of LDL is a risk factor for cardiovascular disease.
ApoB is the major protein component of LDL and plays
an important role in the maintenance of cholesterol homeo-
stasis (1). It serves as the ligand for the recognition and cata-
bolism of plasma LDL by the LDL-receptor (2). Elevated
levels of serum apoB are associated with an increased risk of
premature atherosclerosis (3). Because of its large size and
insolubility in water, the gene structure and amino acid se-
quence of apoB have been difficult to determine. The prima-
ry structure of the carboxyl-terminal end had been deduced
from the nucleotide sequence of the cDNA by Knott et al.
(4). The apoB gene is clearly distinct from other genes of the
soluble apolipoproteins (apoAI, AII, AIV, CI, CII, CIII, and
E). The distribution of the introns in the apoB gene is asym-
metric. No sequence homology has been identified between
apoB and other apolipoproteins. 
ApoB circulates in two distinct forms (apoB100 and apoB48)
encoded by a single gene localized in chromosome 2 pter-
24 (5). ApoB100, the larger form, is synthesized in the liver
as a translational product of the entire apoB mRNA. The
smaller form, apoB48, is produced from the small intestine
by a novel posttranscriptional RNA editing of a CAA (glu-
tamine) to a UAA (stop) codon in apoB mRNA (6, 7). Thus,
apoB48 terminates at amino acid residue 2153 and consists
of the N-terminal 48% of apoB100. ApoB48 lacks the C-
terminal domain of apoB100. As a result, it does not bind
to the LDL-receptor.  ApoB mRNA editing occurs exclusively
in the small intestine of most mammalian species tested,
although some species produce apoB48 even in the liver (8).
Until now, over ten common polymorphisms within or
flanking apoB gene have been detected. Several polymorphic
loci have been recognized in association with total choles-
terol, LDL cholesterol, and apoB levels. In this study, six
polymorphisms (HincII, PvuII, AluI, MspI, EcoRI, and 3′
hypervariable region) of the apoB gene were analyzed in
Korean patients with coronary artery disease (CAD), and
their association with plasma lipid traits was investigated.
Secondly, we compared our data to those in other racial or
ethnic populations studied previously.
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The Haplotype Analyses Using Multiple Markers of the Apolipoprotein
B Gene in Patients with Coronary Artery Disease
The high level of low density lipoprotein (LDL) is a risk factor for cardiovascular
disease. Apolipoprotein (apo) B is a major protein component of LDL and plays
an important role in the maintenance of cholesterol homeostasis. In this study,
six polymorphic sites of the apoB gene were anlaysed in 235 patients with coro-
nary artery disease (CAD) and 216 normal control subjects. There were no sig-
nificant differences in the allele frequencies of apoB polymorphisms between the
control and patient groups. However, haplotype frequencies were significantly
different between the CAD patients and control (p<0.05). In addition, the allelic
distributions of both EcoRI and MspI polymorphisms in Koreans were similar to
those in Chinese but significantly different from those in Caucasians. ApoB poly-
morphisms showed no association with plasma lipid levels. In conclusion, haplo-
type analysis of the apoB gene using multiple diallelic markers might be a useful
marker for Korean CAD patients. 
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MATERIALS AND METHODS
Study subjects
The study subjects were recruited from the Seoul city in
Korea. We selected 235 CAD patients (164 males and 71
females) from Seoul National University Hospital, Korea,
documented by coronary angiography because of recent
myocardial infarction or angina. None of the selected CAD
patients was on a lipid lowering therapy at the time of blood
sampling. In myocardial infarction patients, blood samples
were obtained two months after the occurrence of the myocar-
dial infarction. Patients with hypertension, diabetes, and
endocrine or metabolic disorders were excluded from this
group. The control group consisted of 216 individuals (162
males and 54 females), within the same age range as the
patients, who were randomly selected by health screening at
the same hospital to screen out those who had a history of
chest pain, diabetes, hypertension, and general illness. Mean
ages of CAD patients and controls were 53.2±9.3 and 51.1
±9.1, respectively: the age difference was not statistically
significant. Clinical details for these groups are summarized
in Table 1. Blood samples were collected from all subjects
after a fast of 12-16 hr to exclude the fluctuations of lipid lev-
els. Plasma samples were stored at -70℃ until the time of
lipid assay.
DNA analysis
Total genomic DNA was prepared from  leukocytes of 10
mL blood after lysis of red blood cells (9). Polymorphic
regions of the apoB gene were amplified by polymerase
chain reaction (PCR) from genomic DNA (Fig. 1). Primer
sequences and procedures for PCR amplification have previ-
ously been described (10). Five polymorphic sites are caused
by single base substitutions in various exons and introns in
the apoB gene. The amplified PCR products were digested
at specific restriction sites of endonucleases; namely, HincII,
PvuII, AluI, MspI, and EcoRI. Genotype analyses were done
by electrophoresis on an agarose gel, except for use of 8%
polyacrylamide gel in case of 3′ hypervariable region (HVR)
polymorphism of the apoB gene. Alleles of each polymorphic
site were classified as (+) or (-) according to the presence or
absence at the cutting site of each restriction enzyme, respec-
tively. The 3′ HVR polymorphism is produced by differences
of 15-bp repeat at 491 bp 3′ of the translational termination
site. Alleles of the 3′ HVR polymorphism were determined
according to the nomenclature of Ludwig et al. (11) based
on their 15 base repeats. Haplotype frequencies of the apoB
gene in Koreans were also determined according to method
of Thompson et al. (12).
Determination of lipid levels
Levels of plasma cholesterol and triglyceride were measured
by enzymatic colorimetry methods using commercial kits
(Boeringer Mannheim, FRG) on a Hitachi 747 automatic
chemistry analyzer. HDL-cholesterol was determined by
measuring cholesterol in the supernatant liquid after precipi-
tation of the plasma with MgCl2 and dextran-sulfate, using
a Gilford Impact 400E automatic analyzer with reagents
and calibrators from Boeringer Mannheim, Germany. LDL-
cholesterol levels were calculated by using the formula of
Friedwald et al. (13).
Data analysis 
Heterozygosity (H) and polymorphism information con-
tent (PIC) values of the apoB gene were calculated according
to the method of Botstein et al. (14). Five diallelic markers
within the apoB gene were used for haplotyping. The degree
of nonrandom association was determined by calculation of
the delta value ( ) between the two polymorphic sites at the
apoB gene (15). The  2 test was used to apply for Hardy-
Weinberg equilibrium and to compare allele frequencies
between the CAD and control groups, while the one-way
analysis of variance (ANOVA) test was performed to com-
pare the mean levels of lipid parameters among different
genotypes. All statistical analyses were performed using the
Statistical Analysis System software (SAS Institute, Inc). Sta-
tistical significance was accepted at the p=0.05 level.
RESULTS
Allele frequencies of the six polymorphic sites of the apoB
gene in CAD patients and controls are shown in Table 2. Any
Age 51.1±9.1 53.2±9.3 NS
�
Cholesterol 5.11±0.96 5.72±1.12 0.0026
Triglyceride 1.23±0.61 1.53±0.78 0.0010
HDL-cholesterol 1.51±0.36 0.97±0.27 0.0001
LDL-cholesterol 3.12±0.85 3.21±1.04 NS
Variables p*
Table 1. Mean age (yr±SD) and lipid levels (mmol/L±SD) of
the study subjects
Subjects
Control (n=216) CAD (n=235)
*p value by Chi-square test in lipid levels between the control and CAD
groups, 
� not significant.
Fig. 1. Schematic diagram showing the polymorphic sites of the
apoB gene.
I/D
Exon 1 4 5 14 26 29
HincII
PvuII AluI XbaI EcoRI
MspI 3′ HVR
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of the polymorphisms in this study did not show significant
differences in allele frequencies between patients and controls.
The values of heterozygosity (H) and polymorphism infor-
mation content (PIC) values based on the allele frequencies
of each polymorphism were also estimated. The H and PIC
values for the 3′ HVR polymorphism were relatively high
in the control and CAD groups. Genotype distributions did
not differ from those expected for Hardy-Weinberg propor-
tions at all polymorphic sites. Unequivocal assignments of
haplotypes can be made for all but the doubly heterozygous
individuals. Two polymorphisms (insertion/deletion and
XbaI) previously reported by authors (16) were added to the
haplotype analysis. From 7 diallelic markers within the struc-
I/D* -- 32 16 - 0.38 0.26 0.47/0.38 0.36/0.31
+ - 99 90 + 0.62 0.74
+ + 85 129
HincII -- 160 169 - 0.87 0.86 0.23/0.24 0.20/0.21
+ - 56 66 + 0.13 0.14
+ + 0 0
PvuII -- 208 215 - 0.98 0.96 0.04/0.08 0.04/0.08
+ - 8 20 + 0.02 0.04 
+ + 0 0
AluI -- 148 155 - 0.84 0.83 0.27/0.28 0.24/0.24
+ - 68 80 + 0.16 0.17
+ + 0 0
XbaI* -- 195 209 - 0.95 0.94 0.10/0.11 0.10/0.11
+ - 21 25 + 0.05 0.06
+ + 0 1
MspI -- 00 - 0.00 0.00 0.00/0.00 0.00/0.00
+ - 0 0 + 1.00 1.00
+ + 216 235
EcoRI -- 00 - 0.02 0.05 0.04/0.10 0.04/0.10
+ - 8 22 + 0.98 0.95
+ + 208 213
3′ HVR <36 0.19 0.14 0.75/0.76 0.68/0.69
36 0.62 0.66
>36 0.19 0.20
Polymorphic 
Site
H 
Control/CAD
PIC 
Control/CAD
Table 2. Comparison of allele frequencies of the apoB polymorphisms in the CAD patients and controls
Genotype frequency
Control CAD
Allele frequency
Control CAD
*Insersion/deletion (I/D) and XbaI polymorphisms were reported by authors (16).
Abbreviations: CAD, coronary artery disease; HVR, hypervariable region; H, heterozygosity; PIC, polymorphism information content.
+  ----+ + 3 (2.9)
+ ---++- 1 (0.9) 1 (1.0)
+  ---+  + +  68 (58.5) 69 (65.6)
+  --+  - + + 2  (1.7)
+  --+ +  +  + 2 (1.7) 5 (4.8)
+  - + - +  +  + 1 (0.9) 1 (1.0)
+  --+ + + + 8  (6.9) 10  (9.5)
- + --+ + + 30  (25.9)* 13 (12.3)*
---+  + +  + 1 (0.9) 3 (2.9)
--+ + + + + 1  (0.9)
- +  --+ + +  2  (1.7)
Total number 116 (100.0) 105 (100.0)
Haplotype Number (%)
I/D HincII PvuII AluI XbaI MspI EcoRI Control CAD
Table 3. Haplotype frequencies of the apoB gene in the con-
trol and CAD group
*There is significantly different in the haplotype frequency between
controls and CAD patients.
Control
I/D 0.0470 - 0.0017 0.0687 - 0.0586 - 0.0806
HincII 0.2282 - 0.0517 - 0.1251 - 0.0523 - 0.0431
PvuII 0.0176 1.0000 - 0.1118 - 0.0247 - 0.0213
AluI 0.1529 1.0000 0.4178 - 0.0326 - 0.0471
XbaI 1.0000 1.0000 1.0000 1.0000 - 0.0213
EcoRI 1.0000 1.0000 1.0000 0.1000 1.0000
CAD
I/D - 0.1748 - 0.0455 0.1112 - 0.1116 - 0.0633
HincII 1.0000 - 0.0605 - 0.0985 - 0.0867 - 0.0756
PvuII 1.0000 1.0000 0.0163 - 0.0612 - 0.0502
AluI 0.1609 0.6394 0.0407 - 0.1321 0.0001
XbaI 1.0000 1.0000 1.0000 0.3014 - 0.0510
EcoRI 1.0000 1.0000 1.0000 0.0072 1.0000
D/ I/D HincII PvuII AluI XbaI EcoRI
Table 4. Standardized nonrandom association statistics (D’ , )
between pairs of DNA polymorphisms of the apoB gene
There was no significant linkage disequilibrium between each pair of
polymorphism.722 S.H. Hong, J. Song, J.Q. Kim
tural gene, except the 3′ HVR polymorphism, we could
identify 11 different haplotypes out of a possible total of 128
(Table 3). The +/-/-/-/+/+/+ haplotype was the most com-
mon in both groups. The second most common haplotype,
-/-/-/-/+/+/+, was significantly more frequent in the con-
trols than in patients. However, each polymorphic pair did
not show linkage disequilibrium (Table 4).
We also examined whether five diallelic and 3′ HVR poly-
morphisms of the apoB gene were associated with plasma
lipid levels in Koreans. Any of the polymorphic sites were
not associated with plasma lipid levels.
DISCUSSION
CAD is a multifactorial disease that may differ in each race
or ethnic population. For example, the prevalence of CAD
vary widely among different population, and the frequencies
of the apoB gene polymorphisms have been reported to vary
among ethnic groups. Thus, we investigated polymorphisms
of the apoB gene in Korean CAD patients.
Haplotype determination with multiple markers could
possibly help to define more specific genotypes associated
with high CAD risk than a single marker. From seven allel-
ic polymorphic sites, we could identify the eleven different
haplotypes out of a possible total of 128. The -/-/-/-/+/+/+
haplotype was more frequent among controls than in patients.
This haplotype may be in a linkage disequilibrium with
other functionally important polymorphisms in the apoB
gene. Thus, it is suggested that, at least in Koreans, this
haplotype is likely to be a protective marker against CAD.
The haplotype analysis using multiple markers of the apoB
gene was mainly conducted in 3,500 mutation study (17). 
Until now, the genetic variation of apoB has been studied
extensively. Allele frequencies of the apoB gene in Koreans
were compared with previous studies in various populations.
Among six polymorphisms of this study, the (-) allele fre-
quency of EcoRI polymorphism of Mongoloids (2-5%; 18,
19, 20) was significantly lower than that of Caucasoids (11-
47%; 21-27). Indians in Singapore had the (-) allele frequen-
cy of 10% (28). Also, of interest, MspI polymorphism of
this study did not have the mutant compared to that of
Caucasians (0.07-0.22%; 21, 23, 29) previously studied.
And hence, they seem to be the valuable marker for popula-
tion study.
Five diallelic apoB polymorphisms of this study were not
associated with plasma lipid levels. We could not exclude
the possibility that an appearance of many subjects having
(+ +) or (-- ) homozygote in each polymorphic site may
cause the failure to show the association with lipid levels.
Until now, the association studies between apoB polymor-
phism and lipid phenotypes have reported contradictory
results among populations. Generally, apoB diallelic poly-
morphisms in Asian populations were not associated with
lipid levels (20, 30-32). However, apoB polymorphisms in
Caucasian populations show more polymorphic than those
in Oriental populations as we described at above. Actually
associations between apoB polymorphisms and lipid levels
were mainly reported in Caucasian populations. For example,
Glisic et al. (33) have reported association between EcoRI
and MspI polymorphisms of the apoB gene and lipid levels
in Yugoslavian population. This associations were confirmed
in English (34), Finns (35), Canadian (36, 37), Norwegian
(38) and Danish (39) populations. Also, HVR polymorphism
of this study showed the lack of association with lipid levels.
Japanese population show the same trend (40). However, an
association between the larger 3′ HVR alleles and CAD pa-
tients was reported in Austrian individuals (41). This popu-
lation also showed associations with serum cholesterol and
apoB levels. Alavantic et al. (42) have reported association
between 3′ HVR polymorphism and lipid levels. Thus,
polymorphisms of the apoB gene may be Caucasian-specific.
That is, they may originate from Caucasian populations.
Therefore, it raises the possibility that lack of association
between apoB polymorphisms and lipid levels in non-Cau-
casian populations may, at least in Koreans, partly explain
the rarity of CAD.
As a possible explanation for the differences of allele fre-
quency and lipid association of the apoB polymorphisms
among populations studied, the differences in the genetic
background may be a more important factor than environ-
mental variations, such as diet or life-style. That is, the results
suggest that this genetic link may, at least in part, explain
the differences in prevalence rate of atherosclerosis among
populations. Another possibility is that they may be due to
the differences in linkage disequilibria between the two
polymorphic sites of the apoB gene among populations.
Genetic drift by a founder effect or selective mechanism
may cause different levels of linkage disequilibria. And they
could be caused by the differences of sample numbers and
the bias of sample selection for the populations studied. In
other words, to compare the exact allele heterogeneity among
populations, large sample sizes in order to maintain a statis-
tical power is required, making it possible to identify more
exact distributions of the polymorphisms among racial or
ethnic populations. Thus, polymorphism studies should be
performed ideally on samples from a population of homoge-
nous origin. Population admixture may cause a falsely posi-
tive genetic association. In this respect, Koreans have had a
very low rate of interracial marriage, maintaining a homo-
geneous population for a long time, suggesting that they
are appropriate for polymorphism study. 
In conclusion, the results of this study suggest that, at least
in the Korean population, a single polymorphism of the apoB
gene is unlikely to be a useful marker for CAD patients. How-
ever, haplotypes of the apoB gene are likely to be more use-
ful markers for Korean CAD patients. Haplotype of the apoB gene 723
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